Tagged with japan

Pharma Legal Handbook The low-down on the situation regarding preclinical & clinical trial requirements in Japanese Pharma. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an extract from The Pharma Legal Handbook: Japan, available to purchase here for GBP 149.   1. Are clinical trials required to…

Pharma Legal Handbook An intro to the legal situation for regulatory, pricing and reimbursement in Japan. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an extract from The Pharma Legal Handbook: Japan, available to purchase here for GBP 149.   1. What are the regulatory authorities…

Asia-Pacific Writing in the June edition of DIA’s Global Forum magazine, Ellen Sem, Fengyun (Vicky) Han and Annetta C. Beauregard from Janssen Pharmaceutical Companies of Johnson & Johnson, outline the real-world data (RWD) and real-world evidence (RWE) regulatory landscape in Asia Pacific.  Real-world data (RWD) and real-world evidence (RWE) have played an…

Japan The latest healthcare and pharma news from Japan, including Shionogi’s COVID-19 pill, the Japanese parliament’s green light for emergency approvals of drugs and vaccines and Hitachi’s partnership with Invivoscribe.   Shionogi’s COVID-19 pill  (Reuters) The future of Shionogi & Co Ltd’s experimental treatment, S-217622, is still uncertain. The company recently…

Japan Japanese firm Kirin, part of the Mitsubishi Group and best known for its brewing operations, has pledged to invest JPY 100 billion (USD 870 million) into its healthcare/pharma operations amid a slowdown in the Japanese beer market.   Beer Today, Gone Tomorrow Japan’s rapidly ageing population and the effects of…

Japan A roundup of the latest news from Japanese pharma, including Kirin’s USD 870 million investment in its healthcare and pharmaceuticals businesses over the next three years, Sanofi’s world-first approval for its Niemann-Pick types A/B and B medicine in Japan, and the prospect of domestically developed COVID-19 vaccines being rolled out…

Japan An overview of the new medicines approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) between April and November 2021. See the 2020 data here and the full PMDA approval archive here. Made with Visme Infographic Maker

Global Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more.   1. United States Way out in first place with a market value of USD 533.5 billion in sales in 2020,…

Japan Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise real-world data (RWD) and real-world evidence (RWE) in its regulatory decision-making processes and how this will evolve moving forward.  …

Japan Writing in the August edition of DIA’s Global Forum, Kotone Matsuyama of the Nippon Medical School gives a run-through of Japan’s response to the COVID-19 pandemic, from the organisation and communication of the country’s public health apparatus to the rollout of treatments and vaccines and the growing use of remote auditing…

Japan Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden of cancer in Japan, how Takeda’s solutions help meet some of the country’s most significant unmet cancer needs, as well…

Global As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the…